基于“上下交损,当治其中”探讨心血管–肾脏–代谢综合征的病机与辨治
Exploring the Pathogenesis and Syndrome Differentiation-Based Treatment of Cardiovascular-Kidney-Metabolic Syndrome Based on “When Both the Upper and Lower Are Affected, Treatment Should Target the Middle”
摘要: 心血管–肾脏–代谢综合征(CKM)是一种多系统交互紊乱的复合疾病,旨在描述肥胖、糖尿病、慢性肾脏病与心血管疾病之间的生理病理相互作用,早期以代谢紊乱为主,后期进展为心肾损伤及多器官功能紊乱。“上下交损,当治其中”出自叶天士《临证指南》,核心为上下脏腑受损,病变累及整体,治疗当以调理中焦脾胃为关键。本文基于“上下交损,当治其中”理论,结合心血管–肾脏–代谢综合征“心肾同病、代谢失序”的病理特征,认为其病机演变以脾胃失运、气机失调为病发之始,以痰瘀互结、心肾受累为病进之渐,以中焦衰败、心肾俱损为病重之势。治疗上,主张从中焦脾胃论治,遵循澄源、截流、固本三步治法,分期为中医药临床辨治心血管–肾脏–代谢综合征提供一定的理论依据与实践参考。
Abstract: The Cardiovascular-Renal-Metabolic Syndrome is a complex disorder characterized by multisystem dysregulation, aimed at describing the physiopathological interactions among obesity, diabetes mellitus, chronic kidney disease, and cardiovascular diseases; in its early stages, the condition is primarily marked by metabolic disturbances, whereas in advanced stages, it progresses to cardiac and renal impairment as well as multi-organ dysfunction. The principle “When both upper and lower systems are affected, treatment should target the middle system” is derived from Ye Tianshi’s Clinical Practice Guide; its core idea is that when the upper and lower visceral systems are compromised, the pathological changes affect the entire body, and treatment should focus on regulating the spleen and stomach in the middle jiao. Based on this principle and considering the pathological characteristics of the Cardiovascular-Renal-Metabolic Syndrome—namely the co-occurrence of cardiac and renal pathologies alongside metabolic dysregulation—this article posits that its pathogenesis begins with impaired spleen-stomach function and disrupted qi movement, progresses through the interplay of phlegm and blood stasis along with the involvement of the heart and kidneys, and culminates in the decline of the middle jiao coupled with simultaneous impairment of the heart and kidneys. In terms of treatment, this approach advocates addressing the condition through interventions targeting the spleen and stomach in the middle jiao, adhering to a three-step therapeutic strategy—clarifying the root cause, intercepting pathological flow, and reinforcing the fundamental constitution. This framework provides a theoretical basis and practical reference for the clinical differentiation and treatment of the Cardiovascular-Renal-Metabolic Syndrome using traditional Chinese medicine across different disease stages.
文章引用:申珊, 郭煦, 耿冰倩, 樊威伟. 基于“上下交损,当治其中”探讨心血管–肾脏–代谢综合征的病机与辨治[J]. 中医学, 2026, 15(10): 117-125. https://doi.org/10.12677/tcm.2026.1510533

参考文献

[1] Ndumele, C.E., Rangaswami, J., Chow, S.L., Neeland, I.J., Tuttle, K.R., Khan, S.S., et al. (2023) Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory from the American Heart Association. Circulation, 148, 1606-1635.
https://doi.org/10.1161/cir.0000000000001184
[2] He, D., Zhang, X., Li, C., Yang, C., Yu, M., Wang, J., et al. (2025) Rising Prevalence of Cardiovascular-Kidney-Metabolic Syndrome in China, 2010-2019: National Cross-Sectional Surveys. JACC, 86, 213-216.
https://doi.org/10.1016/j.jacc.2025.05.030
[3] 付子康, 李海英, 李屏. 钠-葡萄糖协同转运蛋白2抑制剂治疗2型糖尿病合并冠心病的研究进展[J]. 中国全科医学, 2022, 25(12): 1493-1499.
[4] 王婷, 王萍, 尚鑫, 等. 胰高血糖素样肽-1受体激动剂降低血糖、减轻体重外的获益分析[J]. 中国新药与临床杂志, 2025, 44(11): 830-836.
[5] 马君, 王敏, 陶梦圆, 等. GLP-1/GIP双受体激动剂替西帕肽改善db/db小鼠代谢相关脂肪性肝病[J]. 南京医科大学学报(自然科学版), 2024, 44(10): 1344-1352.
[6] 中华医学会心血管病学分会心血管专病队列与注册研究学组, 广东省医学会心血管病学分会, 广东省医师协会心脏病器械辅助治疗医师分会, 等. 心血管-肾脏-代谢综合征联合用药与个体化选择治疗专家共识[J]. 暨南大学学报(自然科学与医学版), 2026, 47(1): 1-20.
[7] Nicze, M., Dec, A., Borówka, M., Krzyżak, D., Bołdys, A., Bułdak, Ł., et al. (2024) Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy. International Journal of Molecular Sciences, 25, Article No. 8202.
https://doi.org/10.3390/ijms25158202
[8] 袁卫玲, 苏玮莲, 马佐英, 等. 论中医脾功能变化与糖脂代谢关系[J]. 中国中医药信息杂志, 2015, 22(10): 7-8.
[9] 朱坚骐, 陈红波. 基于“肾虚-血瘀-浊毒”交互理论探讨糖尿病肾脏疾病的病机演变规律[J]. 世界中西医结合杂志, 2026, 21(2): 372-376.
[10] 夏经钢, 袁明霞, 蔡晓凌, 等. 心血管-肾脏-代谢综合征患者的综合管理中国专家共识[J]. 中国心血管病研究, 2025, 23(3): 193-228.
[11] 翟钰铭, 周亚滨, 符佳美, 等. 从“痰瘀滞虚”理论探讨冠心病的病因病机及辨证论治[J]. 现代医学与健康研究电子杂志, 2024, 8(20): 138-141.
[12] 敬馥宇, 尹春琳, 夏经钢. 急性心肌梗死患者发病前心血管-肾脏-代谢综合征分期特征分析[J]. 中国心血管病研究, 2024, 22(11): 1046-1051.
[13] 李宁宇, 周庆伟, 王蓓蕾, 等. 参苓白术散现代临床应用及作用机制研究进展[J]. 时珍国医国药, 2026, 37(13): 2592-2600.
[14] 尤金彪, 董金敏, 张斌, 等. 参苓白术散对脾虚湿困证高脂血症患者的临床疗效及对肠道菌群影响[J]. 中国微生态学杂志, 2024, 36(11): 1310-1317.
[15] 杜莹, 贾连群, 冷雪, 等. 香砂六君子汤对脾虚高脂血症大鼠内质网应激PERK信号通路的影响[J]. 中华中医药学刊, 2023, 41(9): 75-78+271.
[16] 韩艺, 韩宇博, 邹国良, 等. 治未病思想指导下加味黄连温胆汤治疗代谢综合征患者心血管危险因素的临床观察[J]. 中国实验方剂学杂志, 2025, 31(9): 142-149.
[17] 宋德超, 王世东, 吕仁和, 等. 基于数据挖掘的国医大师吕仁和教授运用脾胃经中药分期治疗糖尿病经验研究[J]. 世界中医药, 2023, 18(21): 3098-3102+3108.
[18] 董少宁, 李红典, 张勉之. 茵陈失笑散治疗慢性肾衰竭的研究进展[J]. 实用中医内科杂志, 2022, 36(11): 119-122.
[19] 褚明妍. 茵陈失笑散加味治疗CKM 2-3期(肾虚血瘀兼湿浊内蕴证)的临床研究及机制分析[D]: [硕士学位论文]. 天津: 天津中医药大学, 2025.
[20] 赵亮. 茵陈失笑散在慢性肾小球肾炎患者中的抗炎作用及对肾脏功能的影响[J]. 医学理论与实践, 2025, 38(19): 3310-3312.
[21] 潘健, 杨文雪, 赵亚, 等. 补肾活血方对慢性肾脏病3-5期非透析患者肾功能及微炎症状态的回顾性队列研究[J/OL]. 中华中医药学刊, 1-8.
https://link.cnki.net/urlid/21.1546.r.20260319.1232.040, 2026-03-26.
[22] 李露, 王佳玲, 陈玉鹏, 等. 基于“菌群-肠-代谢”轴探讨葛苓百桔颗粒改善心血管-肾脏-代谢综合征模型小鼠糖代谢的作用机制[J/OL]. 中国实验方剂学杂志, 1-12.
https://doi.org/10.13422/j.cnki.syfjx.20260432, 2026-09-30.
[23] 李露, 周扬, 陈鑫, 等. 基于UPLC-MS/MS技术探究葛苓百桔颗粒改善心血管-肾脏-代谢综合征模型小鼠糖脂代谢的作用及药效物质基础[J/OL]. 中国中医基础医学杂志, 1-18.
https://doi.org/10.19945/j.cnki.issn.1006-3250.20260512.001, 2026-09-30.
[24] 唐珊珊, 李泽华, 连凤梅. 基于仝小林态靶理论构建心血管-肾脏-代谢综合征的整合管理体系[J]. 北京中医药, 2025, 44(9): 1090-1094.
[25] 周洪波. 血府逐瘀汤联合西药治疗冠心病合并心房颤动气滞血瘀证临床观察[J]. 中西医结合心血管病电子杂志, 2020, 8(9): 179+187.
[26] 阮智超, 刘江腾, 张华, 等. 从“郁、热、虚、瘀、毒”病机演变探讨心血管-肾脏-代谢综合征的中医药防治[J]. 中医杂志, 2025, 66(7): 680-684.
[27] 樊威伟, 张大宁. 张大宁从虚、瘀、湿、逆论治慢性肾功能衰竭经验[J]. 中医杂志, 2019, 60(11): 916-919.
[28] 胡路, 张志文, 胡晏珍. 热敏灸联合益气化瘀解毒方对CKD 3-4期伴动脉粥样硬化患者影响的临床研究[J]. 实用中西医结合临床, 2023, 23(10): 1-6+12.
[29] Ma, Y.Y., Guo, Q.L., Zhou, L., Zhao, X., Wang, S., Wang, L., et al. (2026) Cardioprotective Effects of Ling-Gui-Zhu-Gan Decoction against Ventricular Remodeling after Acute Myocardial Infarction via ROS/TXNIP/NLRP3 Signaling. Chinese Journal of Integrative Medicine, 32, 506-514.
https://doi.org/10.1007/s11655-026-4033-z
[30] 陈凯丽, 张琳琪, 肖长斌, 等. 真武汤现代临床应用及作用机制研究进展[J]. 辽宁中医杂志, 2026, 53(6): 242-247.